Loading...
XNASCDTX
Market cap232mUSD
Jan 16, Last price  
21.25USD
1D
4.06%
1Q
88.72%
Jan 2017
-89.78%
IPO
-93.01%
Name

Cidara Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:CDTX chart
P/E
—
P/S
3.64
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
27.58%
Rev. gr., 5y
-12.84%
Revenues
64m
-0.60%
000000020,915,00012,067,00049,572,00064,288,00063,905,000
Net income
-23m
L-23.05%
-792,000-1,344,000-11,894,000-32,193,000-48,165,000-55,728,000-59,016,000-40,085,000-72,373,000-43,909,000-29,799,000-22,931,000
CFO
-22m
L-21.22%
0-1,048,000-7,710,000-25,959,000-39,771,000-49,909,000-56,705,000-28,532,000-54,411,000-25,232,000-28,473,000-22,432,000
Earnings
May 13, 2025

Profile

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
URL
https://www.cidara.com/
IPO date
Apr 15, 2015
Employees
73
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
63,905
-0.60%
64,288
29.69%
Cost of revenue
88,388
94,149
Unusual Expense (Income)
NOPBT
(24,483)
(29,861)
NOPBT Margin
Operating Taxes
443
272
Tax Rate
NOPAT
(24,926)
(30,133)
Net income
(22,931)
-23.05%
(29,799)
-32.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
25,963
2,362
BB yield
-37.40%
-4.47%
Debt
Debt current
2,600
1,317
Long-term debt
8,454
1,317
Deferred revenue
4,245
20,525
Other long-term liabilities
(438)
Net debt
(24,724)
(30,097)
Cash flow
Cash from operating activities
(22,432)
(28,473)
CAPEX
(505)
(118)
Cash from investing activities
(505)
(118)
Cash from financing activities
25,984
(951)
FCF
(28,626)
(29,017)
Balance
Cash
35,778
32,731
Long term investments
Excess cash
32,583
29,517
Stockholders' equity
(441,422)
(406,959)
Invested Capital
443,634
413,925
ROIC
ROCE
EV
Common stock shares outstanding
4,371
3,493
Price
15.88
4.98%
15.13
-40.45%
Market cap
69,417
31.39%
52,833
-20.69%
EV
44,693
22,736
EBITDA
(24,365)
(28,636)
EV/EBITDA
Interest
191
Interest/NOPBT